Endurant Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Endurant Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,753	Closed	-$291K	–	51
2023 Q1	$291K	Sell	20,753 -705	-3%	-$10.1K	0.15%	45
2022 Q4	$307K	Sell	21,458 -1,251	-6%	-$19.7K	0.12%	51
2022 Q3	$580K	Sell	22,709 -306	-1%	-$7.68K	0.19%	42
2022 Q2	$654K	Buy	+23,015	New	+$729K	0.23%	44
2021 Q4	–	Sell	-29,838	Closed	-$1.46M	–	78
2021 Q3	$1.46M	Buy	+29,838	New	+$1.46M	0.33%	45
2021 Q2	–	Sell	-58,168	Closed	-$2.07M	–	75
2021 Q1	$2.07M	Buy	+58,168	New	+$1.93M	0.54%	50

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Endurant Capital Management's MRVI Position: Q2 2023 in Review

Endurant Capital Management sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 20,753 shares — an estimated $291K sold.

Endurant Capital Management first reported a position in MRVI in Q1 2021 and held it in 6 quarters. The position peaked at $2.07M in Q1 2021. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

Endurant Capital Management reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
Endurant Capital Management sold 20,753 Maravai LifeSciences shares in Q2 2023, an estimated $291K.
Endurant Capital Management first reported a position in Maravai LifeSciences in Q1 2021 and held it in 6 quarters.
Endurant Capital Management's Maravai LifeSciences position peaked at $2.07M in Q1 2021.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.